A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors
Latest Information Update: 14 Dec 2023
At a glance
- Drugs PRT 2527 (Primary)
- Indications Advanced breast cancer; Chondrosarcoma; Ewing's sarcoma; HER2 negative breast cancer; Male breast cancer; Myxoid liposarcoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- Sponsors Prelude Therapeutics
- 08 Dec 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Dec 2023.
- 14 Oct 2023 Results presented in a Prelude Therapeutics media release.